MX353322B - Modulacion antisentido de la expresion de gcgr. - Google Patents
Modulacion antisentido de la expresion de gcgr.Info
- Publication number
- MX353322B MX353322B MX2014003492A MX2014003492A MX353322B MX 353322 B MX353322 B MX 353322B MX 2014003492 A MX2014003492 A MX 2014003492A MX 2014003492 A MX2014003492 A MX 2014003492A MX 353322 B MX353322 B MX 353322B
- Authority
- MX
- Mexico
- Prior art keywords
- antisense modulation
- gcgr expression
- gcgr
- compositions
- compounds
- Prior art date
Links
- 101150089905 Gcgr gene Proteins 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102100040890 Glucagon receptor Human genes 0.000 abstract 1
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161537007P | 2011-09-20 | 2011-09-20 | |
| PCT/US2012/056249 WO2013043817A1 (en) | 2011-09-20 | 2012-09-20 | Antisense modulation of gcgr expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014003492A MX2014003492A (es) | 2014-11-10 |
| MX353322B true MX353322B (es) | 2018-01-05 |
Family
ID=47914848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014003492A MX353322B (es) | 2011-09-20 | 2012-09-20 | Modulacion antisentido de la expresion de gcgr. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8865674B2 (enExample) |
| EP (2) | EP2758533B1 (enExample) |
| JP (2) | JP6092226B2 (enExample) |
| KR (1) | KR101840512B1 (enExample) |
| CN (2) | CN108410868A (enExample) |
| AU (2) | AU2012312433B2 (enExample) |
| BR (1) | BR112014006587B1 (enExample) |
| CA (1) | CA2849273C (enExample) |
| DK (1) | DK2758533T3 (enExample) |
| ES (2) | ES2796556T3 (enExample) |
| IL (1) | IL231560B (enExample) |
| IN (1) | IN2014CN02736A (enExample) |
| MX (1) | MX353322B (enExample) |
| NO (1) | NO2925947T3 (enExample) |
| RU (1) | RU2598709C2 (enExample) |
| WO (1) | WO2013043817A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013120003A1 (en) | 2012-02-08 | 2013-08-15 | Isis Pharmaceuticals, Inc. | Modulation of rna by repeat targeting |
| PL2992098T3 (pl) * | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| ES2812099T3 (es) | 2014-05-01 | 2021-03-16 | Ionis Pharmaceuticals Inc | Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento |
| US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| CN108064175A (zh) * | 2014-08-04 | 2018-05-22 | 米拉根医疗股份有限公司 | Myh7b的抑制剂及其用途 |
| US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
| US20180036335A1 (en) * | 2015-03-03 | 2018-02-08 | Ionis Pharmaceuticals, Inc. | Compositions for modulating mecp2 expression |
| EP3277830A4 (en) * | 2015-04-02 | 2018-11-21 | REMD Biotherapeutics, Inc. | Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies |
| KR102539587B1 (ko) * | 2015-04-03 | 2023-06-01 | 아이오니스 파마수티컬즈, 인코포레이티드 | Tmprss6 발현을 조절하기 위한 화합물 및 방법들 |
| WO2017059205A1 (en) * | 2015-09-30 | 2017-04-06 | Ionis Pharmaceuticals, Inc. | Combination therapy |
| SG11201901355SA (en) | 2016-08-30 | 2019-03-28 | Regeneron Pharma | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
| US11400161B2 (en) | 2016-10-06 | 2022-08-02 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| CN108174843B (zh) * | 2018-01-24 | 2018-11-13 | 广州市进德生物科技有限公司 | 一种胰高血糖素保护剂及其应用 |
| EP3981431A4 (en) * | 2019-03-14 | 2023-06-28 | Rena Therapeutics Inc. | Nucleic acid complex for modulating ihh expression |
| CN120239607A (zh) | 2022-09-23 | 2025-07-01 | Ionis制药公司 | 用于降低mecp2表达的化合物和方法 |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5227170A (en) | 1989-06-22 | 1993-07-13 | Vestar, Inc. | Encapsulation process |
| US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5527528A (en) | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
| US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| AU1893192A (en) | 1991-03-28 | 1992-11-02 | University Of Tennessee Research Corporation, The | Dna silver staining |
| JP3220180B2 (ja) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
| EP0590090A4 (en) | 1991-06-18 | 1995-04-12 | Univ Temple | SELECTIVE INHIBITATION OF LEUKEMIC CELL PROLIFERATION BY -I (BCR-ABL) ANTISENS OLIGONUCLEOTIDES. |
| JP3169610B2 (ja) | 1991-06-27 | 2001-05-28 | ジーンラブズ テクノロジーズ，インコーポレイテッド | Ｄｎａ結合分子の検出のためのスクリーニングアッセイ |
| US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| US5804383A (en) | 1992-08-21 | 1998-09-08 | The Regents Of The University Of California | Method and assay for detection of the expression of allele-specific mutations by allele-specific in situ reverse transcriptase polymerase chain reaction |
| US5776725A (en) | 1992-08-28 | 1998-07-07 | Zymogenetics, Inc. | Recombinant production of glucagon receptors |
| PL178685B1 (pl) | 1992-08-28 | 2000-06-30 | Zymogenetics Inc | Cząsteczka DNA kodująca receptor glukagonu lub peptyd receptora glukagonu, konstrukty DNA, komórka gospodarza zawierająca konstrukty DNA, peptyd receptora glukagonu i sposoby wytwarzania receptora glukagonu lub peptydu receptora glukagonu |
| US5985558A (en) | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
| US5872242A (en) | 1992-10-05 | 1999-02-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
| US6410324B1 (en) | 2001-04-27 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of tumor necrosis factor receptor 2 expression |
| US5583020A (en) | 1992-11-24 | 1996-12-10 | Ribozyme Pharmaceuticals, Inc. | Permeability enhancers for negatively charged polynucleotides |
| EP0673559A1 (en) | 1992-12-14 | 1995-09-27 | Honeywell Inc. | Motor system with individually controlled redundant windings |
| JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| US5462854A (en) | 1993-04-19 | 1995-10-31 | Beckman Instruments, Inc. | Inverse linkage oligonucleotides for chemical and enzymatic processes |
| ATE235549T1 (de) | 1993-04-30 | 2003-04-15 | Biognostik Ges | Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2 |
| US5534259A (en) | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5563036A (en) | 1994-04-29 | 1996-10-08 | Tularik, Inc. | Transcription factor-DNA binding assay |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5612455A (en) | 1994-07-05 | 1997-03-18 | Tularik, Inc. | Nuclear factors and binding assay |
| US5734039A (en) | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| US5591721A (en) | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
| US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| WO1998039438A1 (en) | 1997-03-07 | 1998-09-11 | Mochida Pharmaceutical Co., Ltd. | Antisense compounds to cd14 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6133246A (en) | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| CA2303299C (en) | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
| WO1999015643A2 (en) | 1997-09-25 | 1999-04-01 | University Of Florida | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE |
| US20030203862A1 (en) | 1998-03-26 | 2003-10-30 | Miraglia Loren J. | Antisense modulation of MDM2 expression |
| US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| WO2000005418A1 (en) | 1998-07-23 | 2000-02-03 | Gen-Probe Incorporated | Methods for detecting and measuring spliced nucleic acids |
| US6228642B1 (en) | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
| US5962673A (en) * | 1998-11-20 | 1999-10-05 | Isis Pharmaceuticals Inc. | Antisense modulation of inhibitor-kappa B kinase-alpha expression |
| US20030087854A1 (en) | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
| US6692959B2 (en) | 1998-11-25 | 2004-02-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of IL-1 receptor-associated kinase-4 expression |
| CA2850318A1 (en) | 1999-02-26 | 2000-08-31 | The University Of British Columbia | Trpm-2 antisense therapy |
| US5998148A (en) | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| DE60033927T2 (de) | 1999-05-04 | 2007-11-29 | Santaris Pharma A/S | L-ribo-lna analoge |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US6492152B1 (en) | 1999-06-15 | 2002-12-10 | The Board Of Regents Of The University Of Oklahoma | Core 1 β3-galactosyl transferases and methods of use thereof |
| US6284538B1 (en) | 1999-07-21 | 2001-09-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PTEN expression |
| AU783874B2 (en) | 1999-11-29 | 2005-12-15 | Avi Biopharma, Inc. | Uncharged antisense oligonucleotides targeted to bacterial 16S and 23S PRNAS and their uses |
| US6869762B1 (en) * | 1999-12-10 | 2005-03-22 | Whitehead Institute For Biomedical Research | Crohn's disease-related polymorphisms |
| US6602857B1 (en) * | 2000-01-18 | 2003-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| US20020055479A1 (en) * | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| US6770486B1 (en) | 2000-02-08 | 2004-08-03 | Isis Pharmaceuticals, Inc. | Optimization of ligand affinity for RNA targets using mass spectrometry |
| US20040241651A1 (en) * | 2000-04-07 | 2004-12-02 | Alexander Olek | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
| WO2001092524A2 (en) | 2000-05-26 | 2001-12-06 | Aeomica, Inc. | Myosin-like gene expressed in human heart and muscle |
| JP2004507236A (ja) | 2000-08-18 | 2004-03-11 | プロスケリア | 骨粗鬆症の診断および治療に有用な調節遺伝子および系 |
| AU2001296412A1 (en) * | 2000-09-29 | 2002-04-08 | Isis Pharmaceuticals, Inc. | Antisense modulation of mekk4 expression |
| AU2002239538A1 (en) * | 2000-12-06 | 2002-06-18 | Deltagen, Inc. | Transgenic mice containing glucagon receptor gene disruptions |
| JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
| AU2003243391A1 (en) | 2002-06-06 | 2003-12-22 | Monsanto Technology Llc | Methods and compositions for production of maize lines with increased transformability |
| US20040023384A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 12 expression |
| WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| AU2003290596B2 (en) | 2002-11-05 | 2011-05-12 | Isis Pharmaceuticals, Inc. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| EP2314691A3 (en) | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
| CN1726008A (zh) * | 2002-12-19 | 2006-01-25 | 阿尔萨公司 | 用于从植入装置中传递的稳定的非水单相凝胶及其制剂 |
| US7399853B2 (en) * | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
| US7750142B2 (en) | 2003-04-28 | 2010-07-06 | Isis Pharmaceuticals, Inc. | Modulation of glucagon receptor expression |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| US20050142581A1 (en) | 2003-09-04 | 2005-06-30 | Griffey Richard H. | Microrna as ligands and target molecules |
| US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
| US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ， インコーポレーテッド | ４’−チオヌクレオシドおよびオリゴマー化合物 |
| JP4642775B2 (ja) | 2003-12-23 | 2011-03-02 | サンタリス ファーマ アー／エス | Ｂｃｌ−２のモデュレーションのためのオリゴマー化合物 |
| US7341835B2 (en) * | 2004-01-13 | 2008-03-11 | Affymetrix, Inc. | Methods of analysis of alternative splicing in mouse |
| US7943754B2 (en) * | 2004-04-02 | 2011-05-17 | Rosetta-Genomics | Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof |
| CN101052717A (zh) * | 2004-05-11 | 2007-10-10 | α基因株式会社 | 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法 |
| AU2005286738A1 (en) | 2004-09-17 | 2006-03-30 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| WO2007035771A2 (en) * | 2005-09-19 | 2007-03-29 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Modulation of glucagon receptor expression |
| PL2314594T3 (pl) | 2006-01-27 | 2014-12-31 | Isis Pharmaceuticals Inc | Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych |
| US7901882B2 (en) | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| DK2363481T3 (en) * | 2006-05-05 | 2017-06-26 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating gene expression |
| ES2366974T3 (es) * | 2006-05-05 | 2011-10-27 | Isis Pharmaceuticals, Inc. | Compuestos y procedimientos para modular la expresión de sglt2. |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| US8278426B2 (en) | 2007-06-08 | 2012-10-02 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| EP3000884B1 (en) * | 2007-11-09 | 2018-09-12 | Ionis Pharmaceuticals, Inc. | Modulation of factor 7 expression |
| EP2222851B1 (en) * | 2007-11-20 | 2017-06-28 | Ionis Pharmaceuticals, Inc. | Modulation of cd40 expression |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
| US11511972B1 (en) | 2019-09-26 | 2022-11-29 | Versatile, Inc. | System for tracking lifting events at a construction site |
-
2012
- 2012-09-20 ES ES18166477T patent/ES2796556T3/es active Active
- 2012-09-20 US US13/623,337 patent/US8865674B2/en active Active
- 2012-09-20 AU AU2012312433A patent/AU2012312433B2/en active Active
- 2012-09-20 BR BR112014006587-0A patent/BR112014006587B1/pt active IP Right Grant
- 2012-09-20 CN CN201810052777.0A patent/CN108410868A/zh active Pending
- 2012-09-20 CN CN201280045717.7A patent/CN103814132B/zh active Active
- 2012-09-20 KR KR1020147007766A patent/KR101840512B1/ko active Active
- 2012-09-20 MX MX2014003492A patent/MX353322B/es active IP Right Grant
- 2012-09-20 JP JP2014531947A patent/JP6092226B2/ja active Active
- 2012-09-20 CA CA2849273A patent/CA2849273C/en active Active
- 2012-09-20 DK DK12834215.1T patent/DK2758533T3/en active
- 2012-09-20 IN IN2736CHN2014 patent/IN2014CN02736A/en unknown
- 2012-09-20 EP EP12834215.1A patent/EP2758533B1/en active Active
- 2012-09-20 ES ES12834215.1T patent/ES2673721T3/es active Active
- 2012-09-20 RU RU2014115215/10A patent/RU2598709C2/ru active
- 2012-09-20 WO PCT/US2012/056249 patent/WO2013043817A1/en not_active Ceased
- 2012-09-20 EP EP18166477.2A patent/EP3401401B1/en active Active
-
2013
- 2013-08-22 NO NO13752632A patent/NO2925947T3/no unknown
-
2014
- 2014-03-17 IL IL231560A patent/IL231560B/en active IP Right Grant
- 2014-09-12 US US14/484,638 patent/US9404114B2/en active Active
-
2017
- 2017-02-08 JP JP2017020906A patent/JP6538736B2/ja active Active
- 2017-09-26 AU AU2017235886A patent/AU2017235886B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX350944B (es) | Modulación antisentido de la expresión de gccr. | |
| MX353322B (es) | Modulacion antisentido de la expresion de gcgr. | |
| MX2012012624A (es) | Modulacion de la expresion de transtiretina. | |
| EP3489360A3 (en) | Modulation of nuclear-retained rna | |
| MX353152B (es) | Modulación de expresión de huntingtina. | |
| IL284530A (en) | RNAI factors, compositions and methods of using them for the treatment of transthyretin-related diseases | |
| MY162715A (en) | Modulation of apolipoprotein ciii (apociii) expression | |
| WO2012174476A3 (en) | Antisense modulation of fibroblast growth factor receptor 4 expression | |
| UA115652C2 (uk) | Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21 | |
| EP4458361A3 (en) | Modulation of ube3a-ats expression | |
| MX341578B (es) | Tratamiento de la osteoartritis y del dolor. | |
| MX383753B (es) | Modulación de la expresión similar a la angiopoyetina tipo 3. | |
| IL231647A0 (en) | Proteins with dual activity for the treatment of metabolic disorders | |
| PH12014501108A1 (en) | Anti-il-36r antibodies | |
| MX2011011839A (es) | Prevencion y tratamiento de la enfermedad de nosema en abejas. | |
| MX340683B (es) | Anticuerpos anti-vla-4. | |
| UY34070A (es) | Método y composición para tratamiento de semillas. | |
| EA201500752A1 (ru) | Способ лечения заболеваний | |
| WO2011156673A3 (en) | Modulation of phosphoenolpyruvate carboxykinase-mitochondrial (pepck-m) expression | |
| MX2014006990A (es) | Tratamiento para diabetes tipo i y tipo ii. | |
| MX351765B (es) | Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares. | |
| HK1196853A (en) | Antisense modulation of fibroblast growth factor receptor 4 expression | |
| HK1196602A1 (zh) | 作為離子通道調節劑的稠合雜環化合物 | |
| FR2978899B1 (fr) | Mangeoire multiple pour animaux, notamment equides | |
| TN2013000404A1 (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: NOXELL CORPORATION |
|
| FG | Grant or registration |